Inactive Instrument

TCR2 Therapeutics Inc.

Equities

TCRR

US87808K1060

Biotechnology & Medical Research

TCR2 Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021

November 10, 2021 at 06:45 am EST

TCR2 Therapeutics Inc. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported net loss was USD 26.24 million compared to USD 16.92 million a year ago. Basic loss per share from continuing operations was USD 0.69 compared to USD 0.56 a year ago. For the nine months, net loss was USD 72.07 million compared to USD 48.67 million a year ago. Basic loss per share from continuing operations was USD 1.91 compared to USD 1.86 a year ago.

Latest news about TCR2 Therapeutics Inc.

TCR2 Therapeutics Inc.(NasdaqGS:TCRR) dropped from NASDAQ Composite Index	23-06-01	CI
TCR2 Therapeutics Inc.(NasdaqGS:TCRR) dropped from S&P Global BMI Index	23-06-01	CI
TCR2 Therapeutics Inc.(NasdaqGS:TCRR) dropped from S&P TMI Index	23-06-01	CI
Adaptimmune Therapeutics plc completed the acquisition of TCR2 Therapeutics Inc. from a group of shareholders.	23-05-31	CI
TCR2 Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Mizuho Securities Downgrades TCR2 Therapeutics to Neutral From Buy, Adjusts Price Target to $1.72 From $20	23-03-24	MT
Wedbush Adjusts TCR2 Therapeutics Price Target to $1.68 From $2.18, Maintains Neutral Rating	23-03-23	MT
North American Morning Briefing : Stock Futures -2-	23-03-21	DJ
North American Morning Briefing : Jobs Report -3-	23-03-10	DJ
Jefferies Downgrades TCR2 Therapeutics to Hold From Buy, Cuts Price Target to $3 From $18	23-03-09	MT
North American Morning Briefing : Stock Futures -3-	23-03-08	DJ
Truist Securities Downgrades TCR2 Therapeutics to Hold From Buy, Cuts Price Target to $3 From $8	23-03-07	MT
HC Wainwright Downgrades TCR2 Therapeutics to Neutral From Buy	23-03-07	MT
Wedbush Lowers TCR2 Therapeutics' Price Target to $2.18 From $4 on Heels of Adaptimmune Merger Announcement, Keeps Neutral Rating	23-03-07	MT
Sector Update: Health Care Stocks Hit by Late Selling	23-03-06	MT
Top Midday Decliners	23-03-06	MT
Top Midday Gainers	23-03-06	MT
Sector Update: Health Care Stocks Back on Positive Ground	23-03-06	MT
Sector Update: Health Care Stocks Edge Higher Premarket Monday	23-03-06	MT
Upcoming Powell Testimony to Congress Underpins US Equity Futures	23-03-06	MT
Top Premarket Decliners	23-03-06	MT
Top Premarket Gainers	23-03-06	MT
Adaptimmune Therapeutics, TCR2 Therapeutics to Merge in All-Stock Transaction	23-03-06	MT
Adaptimmune and TCR2 Therapeutics Inc. Announce Strategic Combination to Create Preeminent Cell Therapy Company for Solid Tumors	23-03-06	CI
Adaptimmune Therapeutics plc entered into a definitive agreement to acquire TCR2 Therapeutics Inc. from a group of shareholders for approximately $110 million.	23-03-05	CI

Chart TCR2 Therapeutics Inc.

Duration

Period

More charts

Company Profile

TCR2 Therapeutics Inc. is a clinical-stage immunotherapy company developing T cell therapies for patients suffering from cancer. The Company's T cell receptor (TCR) Fusion Construct T cells (TRuC-T cells) specifically recognize and kill cancer cells by harnessing the entire T cell receptor (TCR) signaling complex. Its lead TRuC-T cell, which targets solid tumors is gavocabtagene autoleucel (gavo-cel). The Company completed the Phase I portion of its Phase I/II clinical trial for gavo-cel to treat patients with non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma and cholangiocarcinoma. Its other product candidates include TC-510 and TC-520. Its TC-510 is a TRuC-T cell targeting mesothelin-expressing solid tumors which incorporates a PD-1:CD28 chimeric switch receptor. Its TC-520 is the Company's TRuC-T cell targeting CD-70-expressing solid and liquid tumors which incorporates IL-15 pathway enhancements designed to improve T-cell persistence.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	-0.02%	42.11B
LONZA GROUP AG	+48.60%	40.08B
MODERNA, INC.	+5.04%	40B
CELLTRION, INC.	-11.32%	26.87B
ICON PUBLIC LIMITED COMPANY	+5.25%	24.58B
ALNYLAM PHARMACEUTICALS, INC.	-23.83%	18.44B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.62%	11.94B
MEDPACE HOLDINGS, INC.	+22.75%	11.66B
UNITED THERAPEUTICS CORPORATION	+6.44%	11.01B

Other Biotechnology & Medical Research